Mechanism-based target identification and drug discovery in cancer research

Science

Volumn 287, Issue 5460, 2000, Pages 1969-1973

  Gibbs, Jackson B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLOROANILINO) 4 [2 (3 HYDROXYPROPYLAMINO) 4 PYRIDYL]PYRIMIDINE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ARZOXIFENE; CGP 69846A; CGS 27023A; CHLORMETHINE; CILENGITIDE; CISPLATIN; CP 609754; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; IMATINIB; IMC 1C11; ISIS 2503; ISIS 3521; L 778123; LASOFOXIFENE; LONAFARNIB; MARIMASTAT; MERCAPTOPURINE; METHOTREXATE; MIDOSTAURIN; MONOCLONAL ANTIBODY LM 609; OBLIMERSEN; PACLITAXEL; PRINOMASTAT; PROTEIN KINASE INHIBITOR; RALOXIFENE; REBIMASTAT; TAMOXIFEN CITRATE; TANOMASTAT; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CARCINOGENESIS; DNA ALKYLATION; DRUG RESEARCH; DRUG RESISTANCE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GENE THERAPY; HUMANS; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 0034677755     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.287.5460.1969     Document Type: Review

References (53)

1. W. C. Kaelin Jr., J. Clin. Invest. 104, 1503 (1999).
2. B. A. Chabner, C. J. Allegra, G. A. Curt, P. Calabresi, in Goodman and Gilman's the Pharmacological Basis of Therapeutics, J. G. Hardman, A. C. Gilman, L. E. Limbird, Eds. (McGraw-Hill, New York, 1996), pp. 1233-1287.
3. J. M. Bishop, Cell 64, 235 (1991).
4. J. A. Oates, in (2), pp. 780-808.
5. D. Hanahan and R. A. Weinberg, Cell 100, 57 (2000).
6. A. S. Perkins and D. F. Stern, in Cancer: Principles and Practice of Oncology, V. T. DeVita, S. Hellman, S. A. Rosenberg, Eds. (Lippincott-Raven, Philadelphia, 1997), pp. 79-102.
7. C. J. Sherr, Science 274, 1672 (1996).
8. G. I. Shapiro and J. W. Harper, J. Clin. Invest. 104, 1645 (1999).
9. W. C. Hahn et al., Nature Med. 5, 1164 (1999).
10. B. S. Herbert et al. Proc. Natl. Acad. Sci. U.S.A. 96, 14276 (1999).
11. C. Neufeld, T. Cohen, S. Gengrinovitch, Z. Poltorak, FASEB J. 13, 9 (1999).
12. T. de Lange and T. Jacks, Cell 98, 273 (1999).
13. J. Holash, S. J. Wiegand, G. D. Yancopoulos, Oncogens 18, 5356 (1999).
14. J. B. Gibbs and A. Oliff, Cell 79, 193 (1994).
15. T. K. Sawyer, Biopolymers 47, 243 (1998).
16. J. M. Hamby and H. D. H. Showalter, Pharmacol. Ther. 82, 169 (1999).
17. B. P. Eliceiri and D. A. Cheresh, J. Clin. Invest. 103, 1227 (1999).
18. D. C. Heimbrook, A. Oliff, J. B. Gibbs, in (6), pp. 35-45.
19. L H. Hartwell, P. Szankasi, C. J. Roberts, A. W. Murray, S. H. Friend, Science 278, 1064 (1997).
20. M. J. Marton et al., Nature Med. 4, 1293 (1998).
21. D. Fambrough, K. McClure, A. Kazlauskas, E. S. Lander, Cell 97, 727 (1999).
22. J. S. Lanni, S. W. Lowe, E. J. Licitra, J. O. Liu, T. Jacks, Proc. Natl. Acad. Sci. U.S.A. 94, 9679 (1997).
23. P. K. Sorger, M. Dobles, R. Tournebize, A. A. Hyman, Curr. Opin. Cell Biol. 9, 807 (1997).
24. C. L Vogel and J. M. Nabholtz, Oncologist 4, 17 (1999).
25. I. Ojima et at., Proc. Natl. Acad. Sci. U.S.A. 96, 4256 (1999).
26. T. U. Mayer et al., Science 286, 971 (1999).
27. V. C. Jordan, Trends Endocrinol. Metab. 10, 312 (1999).
28. A. S. Levenson and V. C. Jordan, Eur. J. Cancer 35, 1628 (1999).
29. D. P. McDonnell, Trends Endocrinol. Metab. 10, 301 (1999).
30. M. M. Goldenberg, Clin. Ther. 21, 309 (1999).
31. J. Baselga, L. Norton, J. Albanell, Y. M. Kim, J. Mendelsohn, Cancer Res. 58, 2825 (1998).
32. M. X. Sliwkowski et al., Semin. Oncol. 26, 60 (1999).
33. S. Shak, Semin. Oncol. 26. 71 (1999).
34. M. S. Ewer, H. R. Gibbs, J. Swafford, R. S. Benjamin, Semin. Oncol. 26, 96 (1999).
35. B. J. Druker and N. B. Lydon, J. Clin. Invest. 105, 3 (2000).
36. J. D. Moyer et al., Cancer Res. 57, 4838 (1997).
37. D. H. Boschelli, Drugs Future 24, 515 (1999).
38. J. B. Gibbs, J. Clin. Invest. 105, 9 (2000).'
39. A. Gescher, Gen. Pharmacol. 31, 721 (1998).
40. A. Oliff, Biochim. Biophys. Acta 1423, C19 (1999).
41. T. M. Williams, Expert Opin. Ther. Patents 9, 1263 (1999).
42. D. M. Leonard and J. S. Sebolt-Leopold, Drugs Future 24, 1099 (1999).
43. R. P. Beckett and M. Whittaker, Experts Opin. Ther. Patents 8, 259 (1998).
44. Z. Fan and J. Mendelsohn, Curr. Opin. Oncol. 10, 67 (1998).
45. E. Keshet and S. A. Ben-Sasson, J. Clin. Invest. 104, 1497 (1999).
46. J. T. Holmlund, B. P. Monia, T. J. Kwoh, F. A. Dorr, Curr. Opin. Mol. Ther. 1, 372 (1999).
47. F. E. Cotter, Semin. Hematol. 36, 9 (1999).
48. W. R. Sellers and D. E. Fisher, J. Clin. Invest. 104, 1655 (1999).
49. F. McCormick, Cancer J. Sci. Am. 5, 139 (1999).
50. C. Heise et al., Nature Med. 3, 639 (1997).
51. B. A. Foster, H. A. Coffey, M. J. Morin, F. Rastinejad, Science 286, 2507 (1999).
52. G. J. Kelloff, C. C. Sigman, P. Greenwald, Eur. J. Cancer 35, 1755 (1999).
53. I thank my colleagues at Merck for stimulating discussions. In addition, S. Yao, G. Rodan, and N. Kohl provided helpful comments to the manuscript and J. Campbell skillfully prepared Fig. 1.